🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8 results for “sorafenib” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., LENVATINIB, YERVOY 5 mg/ml concentrate for solution for infusion, Sorafenib 200mg Film-Coated Tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  2. Sorafenib

    China SXT Pharmaceuticals

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  3. Sorafenib

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  4. Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  5. Sorafenib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  6. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Pharma Mar S.A.

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  7. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Pharma Mar S.A.

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  8. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources